{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'in a secure, environmentally controlled, and monitored (manual or automated) area in', 'accordance with the labeled storage conditions with access limited to the investigator and', 'authorized site staff.', 'The investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for study treatment accountability, reconciliation, and record maintenance', '(i.e., receipt, reconciliation, and final disposition records).', 'Further guidance and information for the final disposition of unused study treatment are', 'provided in the Study Reference Manual.', 'Under normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. Take adequate precautions to avoid direct eye', 'or skin contact and the generation of aerosols or mists. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor, or GSK study contact.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing occupational', 'hazards and recommended handling precautions either will be provided to the', 'investigator, where this is required by local laws, or is available upon request from GSK.', 'In the case of unintentional occupational exposure notify the monitor, Medical Monitor,', 'or GSK study contact.', '7.6.', 'Treatment Compliance', 'GSK2857916 will be administered intravenously to participants at the site.', 'Administration will be documented in the source documents and reported in the eCRF.', 'Study treatment is based on body weight calculation and may be reduced for toxicity for', 'individual participants according to protocol guidelines.', 'Participants will receive study treatment at the site directly from the investigator or', 'designee, under medical supervision. The date and time of each dose administered in the', 'clinic will be recorded in the source documents and reported in the eCRF. The dose of', 'study treatment and study participant identification will be confirmed at the time of', 'dosing by a member of the study site staff other than the person administering the study', 'treatment and documented in source.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', '64']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Participants will be instructed to inform the investigator prior to starting any new', 'medications from the time of first dose of study treatment until the end of the study (Final', 'Study Visit). Any concomitant medication(s) including non-prescription medication(s)', 'and herbal product(s), taken during the study will be recorded in the electronic case', 'report form (eCRF). Additionally, a complete list of all prior anti-cancer therapies will', 'be recorded in the eCRF.', 'If future changes are made to the list of permitted/prohibited medications, formal', 'documentation will be provided by GSK and stored in the study file. The SRM will be', 'updated to include this information. Any such changes will be communicated to the', 'investigative sites in the form of a letter.', '7.7.1.', 'Permitted Medication(s)', 'Participants should receive full supportive care during the study, including transfusions of', 'blood products, growth factors, and treatment with antibiotics, anti-emetics, antidiarrheal,', 'and analgesics, as appropriate. Concomitant therapy with bisphosphonates is allowed.', 'Participants may receive local irradiation for pain or stability control.', '7.7.2.', 'Prohibited Medication(s)', 'Chronic treatment with oral steroids is prohibited while the participant is on study, unless', 'for treatment of acute complications related to study treatment, or pre-medication prior to', 'GSK2857916 infusion. Steroids may be used to treat infusion-related reactions. Inhaled', 'steroids are allowed for management of asthma or COPD exacerbations. Chronic low', 'dose replacement therapy (less than or equal to 10 mg prednisolone) is allowed in', 'participants with adrenal insufficiency.', 'Concomitant administration of strong P-glycoprotein (P-gp) inhibitors with GSK2857916', 'should be avoided unless considered medically necessary. Please see the SRM for a list', 'of relevant P-gp inhibitors.', 'Elimination pathways for GSK2857916 or cys-mcMMAF in humans have not been', 'characterized, and care should be exercised when combined with potent cytochrome P450', '(CYP) inhibitors, CYP inducers, and transporter modulators.', 'Other prohibited therapies include:', 'Plasmapheresis: prohibited from 7 days prior to first dose through the end of', 'study.', 'Any other anti-cancer therapy not specified in this protocol, and any', 'investigational agents other than GSK2857916.', '7.7.3.', 'Prohibited Device(s)', 'Contact lenses are prohibited while the participant is on study.', '65']\n\n###\n\n", "completion": "END"}